1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D3FD5542F2ACCEAF85258435006A7E09
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/D3FD5542F2ACCEAF85258435006A7E09?OpenDocument
18
19OpenDocument
203.93.75.30
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Optimizing the Size and Improving the Impact of Immunology Field-Based Medical Teams in Major Global Markets: Optimizing Staffing and Resources

ID: 5568


Features:

10 Info Graphics

18 Data Graphics

250+ Metrics

4 Narratives


Pages/Slides: 33


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Optimizing the Size and Improving the Impact of Immunology Field-Based Medical Teams in Major Global Markets: Optimizing Staffing and Resources"

STUDY OVERVIEW

To maximize the impact of immunology-focused field-based medical teams in high-potential global markets, organizations need to have staffing and resource levels that reflect the needs and opportunities of different regions. To provide current immunology field team metrics in North America, Europe and globally, Best Practices, LLC conducted this study to deliver benchmarks around staffing levels, resource allocations, and favored MSL backgrounds.

This study will help companies fill knowledge gaps around key operational areas for immunology-focused field medical teams, including staffing and resourcing in high-potential geographies. Leaders involved with field-based medical teams focused on immunology can utilize this study to create a road map for becoming more effective in high-potential global markets.

This study includes four segments: All Participants, North America, Europe (Germany and UK), and global (countries outside the US).

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Field-Based Medical Team Staffing Levels
  • Thought Leaders Supported by MSL
  • Key Accounts and Payers Supported by MSLs and HOLs
  • MSL Staffing in Product Lifecycle
  • MSL Professional Background
  • Budget Allocated, Revenue Supported


KEY METRICS
  • How many staff are allocated to the following roles (MSL, MSL manager, MSL effectiveness, HOL, HOl manager)
  • On average, how many staff are allocated as MSLs and HOLs
  • On average, how many thought leaders does each MSL support
  • Percentage of thought leaders served by individual MSL who are KOLs versus HCP
  • Do any of your field MSLs support large key accounts (hospitals, care networks, academic centers)
  • How many large key accounts does each MSL support, on average
  • On average, how many payers does each of your HOLs support
  • On average, what percentage of the peak MSL team size are assigned to support a product at each phase of the typical product lifecycle
  • What percentage of your MSLs have worked previously in the following roles
  • On average, how many years of MSL experience do your MSLs have
SAMPLE KEY FINDINGS

  • Product Support & Timing Trends:
  1. MSLs at respondents’ companies support an average of 3 in-line and 2 pipeline products, with U.S., EU5, and global MSLs reflecting this ratio as well.
  2. Benchmark companies show a rapid increase in MSL staffing levels in phase III (-1 year), with teams in North America growing by around 125% from the previous year (phase III (-2 year)). Across all regions, MSL staffing remains at peak capacity through launch and after 2 years post launch, at which point companies reduce field team size.

METHODOLOGY

Best Practices, LLC engaged 16 medical affairs and field-based medical team leaders working in immunology through a benchmarking survey. Eleven leading biopharma companies represented. To provide useful insights for leadership teams, benchmark data is segmented by: Total Benchmark Class, Global (ex-U.S.), North America region and EU5 region. Six deep-dive interviews were conducted with medical affairs leaders, whose insights were provided to enrich the data and add real-world context to the metrics and trends established.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Chemical; Medical Device


Companies Profiled:
Amgen; Allergopharma; Pfizer; Genentech; Shire; Roche; GlaxoSmithKline ; Janssen; EMD Serono; Merck; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.